| Regulus Therapeutics (RGLS) | |||
|---|---|---|---|
| 2.43 -0.22 (-8.3%) | 05-06 16:00 | ||
| Open: | 2.71 | Pre. Close: | 2.65 |
| High: | 2.789 | Low: | 2.4 |
| Volume: | 888,568 | Market Cap: | 159(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 3.03 One year: 3.39 |
| Support: | Support1: 2.09 Support2: 1.74 |
| Resistance: | Resistance1: 2.59 Resistance2: 2.90 |
| Pivot: | 2.38 |
| Moving Averages: | MA(5): 2.52 MA(20): 2.47 MA(100): 1.82  MA(250): 1.57 |
| MACD: | MACD(12,26): 0.04 Signal(12,26,9): 0.03 |
| %K %D: | %K(14,3): 61.73 %D(3): 59.49 |
| RSI: | RSI(14): 50.00 |
| 52-Week: | High: 3.79 Low: 1.08 Change(%): 77.4 |
| Average Vol(K): | 3-Month: 3270 10-Days: 351 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 2.791 - 2.81 | 2.81 - 2.826 |
| Low: | 2.368 - 2.384 | 2.384 - 2.398 |
| Close: | 2.406 - 2.433 | 2.433 - 2.454 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RGLS ] has closed below upper band by 42.8%. Bollinger Bands are 16.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 65.47 |
| Shares Float (M) | 41.55 |
| % Held by Insiders | 1.68 |
| % Held by Institutions | 76.99 |
| Shares Short (K) | 6270 |
| Shares Short Prior Month (K) | 5130 |
| Stock Financials | |
|---|---|
| EPS | -1.580 |
| Book Value (p.s.) | 1.050 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -50.2 |
| Return on Equity (ttm) | -110.3 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -0.472 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -26.77 |
| Levered Free Cash Flow (M) | -16.93 |
| Stock Valuation | |
|---|---|
| PE Ratio | -1.54 |
| PEG Ratio | -0.13 |
| Price to Book value | 2.31 |
| Price to Sales | |
| Price to Cash Flow | -5.94 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
